Intestinal carbohydrate absorption

Intestinal carbohydrate absorption inhibition" is not a single molecular target but rather describes a **therapeutic strategy** aimed at reducing the rate or extent of dietary carbohydrate breakdown and subsequent monosaccharide uptake in the small intestine. This process involves several key proteins: • **Alpha-amylases** initiate starch digestion; their inhibitors slow down polysaccharide breakdown. • **Alpha-glucosidases** on the brush border membrane hydrolyze disaccharides into absorbable monosaccharides; drugs like acarbose inhibit these enzymes to delay glucose release into circulation[1][2]. • **Sodium-dependent glucose transporter 1 (SGLT1)** mediates active transport of glucose and galactose across enterocytes; its blockade reduces postprandial glycemic excursions[3]. • **Glucose transporter 2 (GLUT2)** facilitates facilitated diffusion of glucose from enterocytes into blood. Therapeutic agents targeting these steps are used primarily for managing type 2 diabetes by blunting postprandial hyperglycemia. However, "intestinal carbohydrate absorption inhibition" itself is not a canonical name for any one protein or receptor but refers collectively to interventions at various points in this pathway. Therefore, it is not considered a valid single therapeutic target but rather an umbrella term encompassing several distinct molecular targets involved in intestinal sugar digestion and transport[3].

Other names

Carbohydrate absorption inhibitionInhibition of intestinal carbohydrate uptakeIntestinal glucose absorption inhibition

Inhibition of alpha-amylase and/or alpha-glucosidase to delay carbohydrate hydrolysis and reduce monosaccharide formation; Inhibition of SGLT1 or GLUT2 to block intestinal glucose uptake